DCHA as Postremission Therapy for AML With t(8;21)
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Acute myelocytic leukemia ( AML) is a highly heterogeneous group of malignant hematopathy.
Chromosomal translocation with t (8; 21) (q22; q22) , about 10 ~ 15% incidence in AML and 40%
incidence in the AML-M2 type of leukemia, is a karyotype that is considered to have a good
prognosis. The National Comprehensive Cancer Network (NCCN) guidelines recommend that
high-dose Ara-c regimens may benefit for patients, but with 30 to 40% relapse and serious
risks on myelosuppression, infection and bleeding in high-dose Ara-c consolidation
chemotherapy and more than 70% recurrence rate with （tyrosine kinase）KIT mutation. So the
exploration of a relatively safe and efficient consolidation therapy is one of the difficult
problems to be solved in the treatment of mitigatory t (8; 21) AML.